

Evaluation of Contemporary Experimental Models of Melanogenesis as Tools for the Scientific Validation of Varnya Karma

Zodage Samruddhi Suresh¹, Nangare Ninad^{2*}, Chandrachood Smita³, Pardeshi Pallavi⁴

¹Research Scholar, Department of Dravyaguna, Bharati Vidyapeeth (Deemed to be University) College of Ayurved, Pune – 411046, Maharashtra, India

Email: samruddhizodage14@gmail.com

²Professor and Guide, Department of Dravyaguna, Bharati Vidyapeeth (Deemed to be University) College of Ayurved, Pune – 411046, Maharashtra, India

Email: ninad.nangare@bharativedyapeeth.edu

³Assistant Professor, Department of Dravyaguna, Bharati Vidyapeeth (Deemed to be University) College of Ayurved, Pune – 411046, Maharashtra, India

Email: drsmita886@gmail.com

⁴Assistant Professor, Department of Dravyaguna, Bharati Vidyapeeth (Deemed to be University) College of Ayurved, Pune – 411046, Maharashtra, India

Email: pallavi.pardeshi@bharativedyapeeth.edu

Corresponding Author:

Nangare Ninad

Professor and Guide, Department of Dravyaguna, Bharati Vidyapeeth (Deemed to be University) College of Ayurved, Pune – 411046, Maharashtra, India

Email: (ninad.nangare@bharativedyapeeth.edu)

ABSTRACT

Varnya Karma, a fundamental concept in Ayurvedic dermatology, refers to the therapeutic action of substances that enhance skin complexion and promote healthy skin color. The classical Ayurvedic text Charaka Samhita describes Varnya Mahakashaya, a group of ten herbs specifically designated for complexion enhancement. Despite centuries of traditional use, the scientific validation of Varnya Karma through modern experimental models remains an evolving field that bridges traditional Ayurvedic knowledge with contemporary dermatological research.

This comprehensive review aims to evaluate the scientific validation of Varnya Karma through modern experimental models, including in vitro, in vivo, and clinical approaches. We examine the correlation between Ayurvedic parameters and modern biomarkers of skin pigmentation, providing evidence-based insights into the mechanisms of action of Varnya Dravyas.

Modern experimental models provide substantial evidence validating the traditional concept of Varnya Karma. The multi-modal approach incorporating in vitro tyrosinase inhibition assays, in vivo animal models, and clinical studies offers a comprehensive framework for evaluating complexion-enhancing properties of Ayurvedic herbs. Future research should focus on standardized protocols and molecular mechanisms to establish Varnya Karma as an evidence-based therapeutic modality.

Keywords: Varnya Karma, Ayurveda, Tyrosinase inhibition, Melanogenesis, Hyperpigmentation, Herbal medicine, Skin lightening

How to cite this article: Zodage SS, Ninad N, Smita C, Pallavi P. Evaluation of Contemporary Experimental Models of Melanogenesis as Tools for the Scientific Validation of Varnya Karma. Int J Drug Deliv Technol. 2026;16(61s):1124-1131. DOI: 10.25258/ijddt.16.61s.127

Source of support: Nil.

Conflict of interest: None

INTRODUCTION

Definition of Varnya Karma

Varnya Karma is a classical Ayurvedic concept denoting the therapeutic action of substances that enhance and maintain the natural complexion of the skin. The term "Varna" refers to color or complexion, while "Karma" indicates the pharmacological action or therapeutic effect [1]. In Ayurvedic dermatology, Varnya represents one of the essential therapeutic categories (Karma) specifically targeting the improvement of skin color, clarity, and radiance [2].

The classical Ayurvedic text Charaka Samhita, in its Sutra Sthana (Chapter 4), describes Varnya Mahakashaya a curated group of ten herbs specifically designated for complexion enhancement [3]. These herbs are believed to act through multiple mechanisms including Raktaprasadana (blood purification), Pittashamana (pacification of Pitta dosha), Twakprasadana (skin clarification), and Srotoshodhana (cleansing of microchannels) [4].

Concept of Varna, Twak and Twak Prasadana

*Author for Correspondence: ninad.nangare@bharativedyapeeth.edu

In Ayurvedic physiology, the skin (Twak) is considered one of the seven Dhatus (tissue layers) and serves as the seat of the sense of touch [5]. The term "Varna" encompasses not merely skin color but the overall complexion, including brightness, clarity, and radiance. Twak Prasadana refers to the process of enhancing skin texture and appearance through various pharmacological interventions [6].

The concept of Varna extends beyond aesthetic considerations to encompass the overall health status of an individual. According to Ayurvedic principles, optimal Varna reflects balanced Agni (metabolic fire), proper functioning of the Rakta (blood tissue), and equilibrium of the Doshas, particularly Pitta, which governs color and complexion [7].

Varnya Mahakashaya and Varnya Dravyas

The Varnya Mahakashaya comprises ten herbs selected by Acharya Charaka for their complexion-enhancing properties [3]:

Chandana (*Santalum album* Linn.) - White sandalwood
Punnaga (*Calophyllum inophyllum* Linn.) - Ironwood tree
Padmaka (*Prunus cerasoides* D. Don.) - Himalayan cherry
Ushira (*Vetiveria zizanioides* (Linn.) Nash.) - Vetiver
Madhuka (*Glycyrrhiza glabra* Linn.) - Licorice
Manjistha (*Rubia cordifolia* Linn.) - Indian madder
Sariva (*Hemidesmus indicus* R. Br.) - Indian sarsaparilla
Vidarikand (*Pueraria tuberosa* DC.) - Indian kudzu
Durva (*Cynodon dactylon* (L.) Pers.) - Bermuda grass
Lata (*Cynodon linearis*) - Creeping grass

These herbs are traditionally employed either individually or in complex formulations for the management of various skin discoloration disorders, including Vyanga (melasma), Nyasha (freckles), and other hyperpigmentation conditions [8].

Need for Scientific Validation

Despite the extensive traditional use of Varnya Dravyas in Ayurvedic practice, the scientific validation of their efficacy and mechanisms of action through modern experimental models remains essential for several reasons [9]:

Evidence-based integration: Establishing pharmacological validation enables the integration of Ayurvedic dermatology into mainstream healthcare

Standardization: Modern analytical methods facilitate quality control and standardization of herbal formulations

Mechanism elucidation: Understanding molecular mechanisms provides insights into drug discovery and development

Safety profiling: Rigorous toxicological evaluation ensures the safe use of traditional preparations

Global acceptance: Scientific validation facilitates the acceptance of Ayurvedic therapies in international markets

This review aims to comprehensively evaluate the scientific validation of Varnya Karma through modern experimental models, examining the convergence between traditional Ayurvedic concepts and contemporary dermatological research.

Literature Review

Modern Understanding of Skin Pigmentation

Melanin: The Primary Determinant of Skin Color

Melanin represents the primary pigment responsible for the coloration of human skin, hair, and eyes. It is synthesized by specialized dendritic cells called melanocytes, which are located in the basal layer of the epidermis [10]. Two major types of melanin exist: eumelanin (brown-black pigment) and pheomelanin (yellow-red pigment), with the ratio of these pigments determining the specific skin color phenotype [11].

The biochemical synthesis of melanin, termed melanogenesis, involves a complex cascade of enzymatic reactions with tyrosinase serving as the rate-limiting enzyme [12]. Tyrosinase catalyzes the hydroxylation of L-tyrosine to L-DOPA (3,4-dihydroxyphenylalanine) and the subsequent oxidation of L-DOPA to dopaquinone, which then undergoes a series of spontaneous and enzymatic reactions to form melanin [13].

Melanocytes and Melanogenesis Pathway

Melanocytes are neural crest-derived cells that constitute approximately 10% of the basal layer of the epidermis [14]. These cells possess dendritic processes that extend into the upper epidermal layers, facilitating the transfer of melanin-containing organelles (melanosomes) to neighboring keratinocytes [15].

The melanogenesis pathway involves several key enzymes:
- Tyrosinase (TYR): Catalyzes the initial and rate-limiting steps of melanin synthesis
- Tyrosinase-related protein 1 (TYRP1): Functions in the stabilization of tyrosinase and eumelanin synthesis
- Tyrosinase-related protein 2 (TYRP2/DCT): Catalyzes the tautomerization of dopachrome to 5,6-dihydroxyindole-2-carboxylic acid (DHICA) [16]

Role of Tyrosinase in Pigmentation

Tyrosinase is a copper-containing metalloenzyme that plays a pivotal role in melanogenesis. The enzyme requires two copper ions in its active site for catalytic activity [17]. The inhibition of tyrosinase activity represents the most common mechanism for achieving skin lightening effects, as this enzyme controls the initial and rate-limiting steps of melanin synthesis [18].

Structural studies have revealed that tyrosinase contains a binuclear copper active site coordinated by six histidine residues. Inhibitors can act through various mechanisms including copper chelation, competitive inhibition at the active site, or interference with enzyme maturation and glycosylation [19].

Hyperpigmentation Disorders

Hyperpigmentation disorders represent a significant dermatological concern, affecting individuals across diverse ethnic backgrounds. Common conditions include [20]:

Melasma (Vyanga): Characterized by symmetrical, hyperpigmented patches on the face, particularly the malar areas, forehead, and upper lip. The condition is exacerbated by UV exposure and hormonal factors.

Post-inflammatory hyperpigmentation (PIH): Results from inflammatory skin conditions such as acne, eczema, or injury, leading to increased melanin deposition in affected areas.

Solar lentigines: Age spots or liver spots caused by cumulative UV exposure.

Freckles (Nyasha): Small, concentrated areas of increased melanin, genetically determined and UV-inducible.

Mechanisms of Varnya Karma in Modern Context

Modern research has identified several mechanisms through which Varnya herbs exert their skin-lightening effects [21]:

Direct Tyrosinase Inhibition: Many Varnya herbs contain polyphenolic compounds that inhibit tyrosinase activity through competitive or non-competitive mechanisms.

Antioxidant Activity: Free radical scavenging prevents oxidative stress-induced melanogenesis.

Anti-inflammatory Effects: Reduction of inflammatory mediators decreases melanocyte stimulation.

Melanosome Transfer Inhibition: Interference with the transfer of melanin to keratinocytes.

MITF Downregulation: Suppression of microphthalmia-associated transcription factor, the master regulator of melanogenesis.

Materials & Methods

Search Strategy

A comprehensive literature search was conducted across multiple electronic databases including PubMed, PMC, Google Scholar, and Scopus. The search strategy employed the following keywords and combinations: "Varnya Karma," "Ayurvedic skin herbs," "tyrosinase inhibition," "melanogenesis," "hyperpigmentation," "herbal skin lightening," "melasma treatment," and "clinical trials botanical." The search was limited to English-language publications from 2010 to 2024.

Selection Criteria

Studies were included if they met the following criteria: 1. Evaluation of Ayurvedic herbs traditionally classified as Varnya 2. In vitro assessment of tyrosinase inhibition or melanogenesis modulation 3. In vivo animal studies on skin pigmentation 4. Clinical trials on hyperpigmentation disorders 5. Mechanistic studies on melanogenesis pathways.

Data Extraction

Data extracted from selected studies included: study design, experimental models, test compounds, outcome measures, IC₅₀ values (where applicable), clinical efficacy parameters, and safety data.

Modern Experimental Models

In Vitro Models

Mushroom Tyrosinase Inhibition Assay: This assay utilizes mushroom tyrosinase as a surrogate for human tyrosinase.

The enzyme activity is measured spectrophotometrically by monitoring the conversion of L-DOPA to dopachrome at 475 nm [22].

Cellular Tyrosinase Activity Assay: Melanocyte cell lines (B16 murine melanoma cells, normal human epidermal melanocytes) are treated with test compounds, and intracellular tyrosinase activity is measured using cellular lysates [23].

Melanin Content Assay: Melanin content in treated cells is quantified after solubilization in alkaline DMSO or NaOH, with absorbance measured at 405 nm [24].

Cell Viability Assay: MTT or XTT assays are performed to assess cytotoxicity and ensure that observed effects are not due to cellular toxicity [25].

Antioxidant Assays: DPPH, ABTS, and FRAP assays evaluate free radical scavenging capacity [26].

In Vivo Models

Zebrafish Pigmentation Model: Zebrafish embryos offer a transparent, high-throughput model for evaluating melanogenesis. The embryos develop externally, allowing direct visualization of melanophore development and distribution [27].

UV-Induced Hyperpigmentation Models: UVB irradiation of brownish guinea pig or mouse skin induces hyperpigmentation, mimicking solar lentigines. Test compounds are applied topically, and pigmentation is evaluated using colorimetric methods [28].

Chemical-Induced Hyperpigmentation: Chemical agents such as α -MSH (melanocyte-stimulating hormone) or 8-isoprostaglandin E2 are used to stimulate melanogenesis in animal models [29].

Clinical Evaluation Models

Melasma Studies: Randomized controlled trials evaluate the efficacy of Varnya formulations in melasma patients using standardized assessment tools including MASI (Melasma Area and Severity Index), Mexameter readings, and digital photography [30].

Tanning Studies: UV-induced tanning studies assess the preventive effects of Varnya preparations on UV-induced pigmentation in human volunteers [31].

Objective Assessment Methods: - Mexameter MX 18: Measures melanin index and erythema index by reflectance spectroscopy [32] - Colorimeter: Provides objective color measurements (L, a, b values) [33] - Dermoscopy: Non-invasive examination of skin pigmentary patterns [34] - VISIA Imaging: * Digital facial imaging for quantitative analysis of pigmentation [35]

Results

In Vitro Studies on Varnya Herbs

Tyrosinase Inhibition Activity

Analysis of published studies revealed significant tyrosinase inhibitory activity among Varnya Mahakashaya herbs (Table 1).

Table 1. Tyrosinase Inhibition Activity of Selected Varnya Herbs

Herb	Common Name	IC ₅₀ (µg/mL)	Inhibition Mechanism	Reference
<i>Santalum album</i>	White Sandalwood	171 ± 12	Competitive	[36]
<i>Crocus sativus</i>	Saffron	67 ± 8	Non-competitive	[37]
<i>Phyllanthus emblica</i>	Amla	247 ± 19	Mixed	[38]
<i>Glycyrrhiza glabra</i>	Licorice	45 ± 5	Competitive	[39]
<i>Rubia cordifolia</i>	Indian Madder	189 ± 15	Competitive	[40]
<i>Hemidesmus indicus</i>	Indian Sarsaparilla	234 ± 22	Non-competitive	[41]
<i>Vetiveria zizanioides</i>	Vetiver	312 ± 28	Mixed	[42]

The most potent inhibition was observed with *Glycyrrhiza glabra* (licorice), with an IC₅₀ of 45 µg/mL. The active compound glabridin showed particularly strong inhibition with an IC₅₀ of 0.43 µM, demonstrating 16-fold greater activity than hydroquinone [43].

Comparative Analysis with Standard Agents

Table 2. Comparison of Tyrosinase Inhibition IC₅₀ Values

Compound	IC ₅₀ (µM)	Source	Potency Relative to Kojic Acid
Kojic Acid	70 ± 7	Synthetic	1.0 (Reference)
Glabridin	0.43	<i>Glycyrrhiza glabra</i>	162.8
α-Arbutin	1687 ± 181	Synthetic	0.041
β-Arbutin	6499 ± 137	Synthetic	0.011
Deoxyarbutin	>8000	Synthetic	<0.009
Ascorbic Acid	200	Synthetic	0.35

The data demonstrate that natural compounds from Varnya herbs, particularly glabridin from licorice, exhibit superior tyrosinase inhibitory activity compared to many synthetic agents [44].

Studies on B16 murine melanoma cells revealed that Varnya herb extracts significantly reduced melanin content in a dose-dependent manner. Treatment with *Santalum album* extract at 100 µg/mL reduced melanin content by 45.2% compared to control, while *Phyllanthus emblica* extract achieved 38.7% reduction at the same concentration [45].

Melanin Content Reduction in B16 Cells

Table 3. Melanin Content Reduction in B16 Melanoma Cells

Extract	Concentration (µg/mL)	Melanin Reduction (%)	Tyrosinase Activity Reduction (%)
<i>Santalum album</i>	100	45.2 ± 3.8	52.4 ± 4.1
<i>Phyllanthus emblica</i>	100	38.7 ± 3.2	44.6 ± 3.5
<i>Glycyrrhiza glabra</i>	100	58.3 ± 4.5	61.2 ± 4.8
<i>Rubia cordifolia</i>	100	41.5 ± 3.6	48.3 ± 4.0
Kojic Acid (Control)	100	35.2 ± 3.0	40.1 ± 3.2

In Vivo Studies

Zebrafish Pigmentation Model

The zebrafish model has emerged as a valuable tool for evaluating Varnya activity. Treatment with *Artemisia*

capillaris extract at 100 µg/mL reduced melanin pigmentation by 42.3% in zebrafish embryos without affecting viability [46]. Similar studies with *Gastrodia elata* extract demonstrated dose-dependent inhibition of melanogenesis [47].

UV-Induced Hyperpigmentation in Animal Models

Studies on UVB-induced hyperpigmentation in brownish guinea pigs demonstrated that topical application of *Glycyrrhiza glabra* extract (2%) significantly reduced UV-induced pigmentation compared to vehicle control (p<0.01) [48]. Histological examination revealed decreased melanin deposition in the basal layer of the epidermis.

Clinical Studies

Melasma Treatment Trials

A systematic review and meta-analysis of 12 randomized controlled trials evaluating botanical products for melasma revealed significant clinical efficacy [49].

Table 4. Clinical Efficacy of Botanical Products for Melasma

Outcome Measure	Effect Size	95% Confidence Interval	p-value
MASI Reduction	SMD -0.79	-1.14 to -0.44	<0.00001
Mexameter Reading	SMD -0.52	-0.81 to -0.23	0.0005
Melanin Index	SMD -0.63	-0.95 to -0.31	0.0001

Safety Profile

Pooled data from clinical trials demonstrated that botanical products were well-tolerated, with no serious adverse events reported [50]. The incidence of adverse events was significantly lower in the botanical product group (3.2%) compared to active comparators (12.5%) (RR 0.37, 95% CI: 0.15-0.88, p=0.02).

Table 5. Adverse Events in Clinical Trials

Treatment Group	Number of Patients	Adverse Events (%)	Relative Risk	p-value
Botanical Products	187	6 (3.2%)	0.37	0.02
Active Comparators	160	20 (12.5%)	Reference	-

Mechanistic Studies

Molecular Targets

Modern mechanistic studies have identified several molecular targets of Varnya herbs [51]:

Table 6. Molecular Targets of Varnya Herbs

Target	Mechanism	Herb Examples
Tyrosinase	Direct enzyme inhibition	<i>Glycyrrhiza glabra</i> , <i>Santalum album</i>
MITF	Downregulation of transcription factor	<i>Phyllanthus emblica</i> , <i>Rubia cordifolia</i>
TRP-1	Inhibition of related protein	<i>Hemidesmus indicus</i>
TRP-2	Inhibition of dopachrome tautomerase	<i>Vetiveria zizanioides</i>
MC1R	Modulation of melanocortin receptor	<i>Crocus sativus</i>

Signaling Pathway Modulation

Research has demonstrated that Varnya herbs modulate multiple signaling pathways involved in melanogenesis [52]:

cAMP/PKA Pathway: Inhibition of cAMP production reduces MITF expression

MAPK Pathway: ERK activation promotes MITF degradation

PI3K/AKT Pathway: Modulation affects melanocyte survival and function

Wnt/ β -catenin Pathway: Regulation influences melanocyte development

The present review demonstrates a significant convergence between traditional Ayurvedic concepts of Varnya Karma and modern dermatological understanding of skin pigmentation mechanisms. The multi-modal experimental approach provides comprehensive validation of the traditional therapeutic claims [53].

Varnya Karma → Reduction in Melanin Synthesis

The traditional concept of Varnya Karma as enhancement of skin complexion correlates directly with the modern understanding of melanin synthesis inhibition. The in vitro and in vivo studies demonstrate that Varnya herbs significantly reduce melanin content through inhibition of tyrosinase activity and modulation of melanogenesis pathways [54].

DISCUSSION

Correlation of Modern Models with Ayurvedic Concepts

Twak Prasadana → Improved Skin Texture

The Ayurvedic concept of Twak Prasadana (skin clarification) aligns with modern observations of improved skin texture and barrier function following treatment with Varnya formulations. Clinical studies have demonstrated enhanced skin hydration, elasticity, and overall quality parameters [55].

Raktaprasadana → Anti-inflammatory and Antioxidant Effects

The traditional concept of Raktaprasadana (blood purification) corresponds to the modern understanding of anti-inflammatory and antioxidant mechanisms. Many Varnya herbs exhibit potent free radical scavenging capacity and modulation of inflammatory mediators, which indirectly affect melanogenesis [56].

Pitta-Rakta Balance → Melanogenesis Regulation

The Ayurvedic concept of Pitta-Rakta balance in maintaining optimal skin color correlates with the modern understanding of melanogenesis regulation. The modulation of melanocyte function and melanin distribution represents the physiological basis for this traditional concept [57].

Efficacy and Safety Profile

The clinical trial data demonstrate that botanical products derived from Varnya herbs are effective for treating hyperpigmentation disorders, with efficacy comparable to synthetic agents but with a superior safety profile [58]. The significantly lower incidence of adverse events with botanical products suggests they may be preferable for long-term use in chronic conditions such as melasma [59].

Mechanistic Insights

The mechanistic studies reveal that Varnya herbs act through multiple complementary pathways, consistent with the Ayurvedic concept of polyherbal formulations and multi-target therapy [60]. This polypharmacological approach may explain the sustained efficacy and favorable safety profile observed in clinical studies [61].

Challenges in Validation

Despite the promising results, several challenges remain in the scientific validation of Varnya Karma [62]:

Standardization: Lack of standardized extracts and formulations makes comparison across studies difficult

Biomarkers: Absence of validated Ayurvedic biomarkers for Varnya effects

Clinical Assessment: Variability in clinical outcome measures and assessment protocols

Correlation: Difficulty in establishing direct correlations between traditional Ayurvedic parameters and modern biomarkers

Quality Control: Variability in herbal raw materials and preparation methods

Future Directions

Future research should focus on [63]:

Standardized Protocols: Development of validated protocols for Varnya evaluation incorporating both traditional and modern parameters

Omics Approaches: Application of transcriptomics, proteomics, and metabolomics to understand the holistic effects of Varnya formulations

AI-Based Analysis: Utilization of artificial intelligence for skin image analysis and correlation with Ayurvedic parameters

Molecular Docking: Computational studies to identify potential bioactive compounds and their interactions with molecular targets

Long-term Safety: Longitudinal studies to evaluate the safety and efficacy of prolonged Varnya therapy

CONCLUSION

This comprehensive review demonstrates that modern experimental models provide substantial evidence validating the traditional Ayurvedic concept of Varnya Karma. The multi-modal approach incorporating in vitro tyrosinase inhibition assays, in vivo animal models, and clinical studies offers a robust framework for evaluating the complexion-enhancing properties of Ayurvedic herbs.

Key findings include:

Varnya herbs exhibit significant tyrosinase inhibitory activity, with IC₅₀ values comparable or superior to synthetic agents

Clinical trials demonstrate efficacy in hyperpigmentation disorders with a favorable safety profile

Mechanistic studies reveal multi-target action consistent with Ayurvedic principles

The convergence of traditional knowledge and modern science supports the integration of Varnya formulations into evidence-based dermatological practice

Future research should focus on standardized protocols, molecular mechanisms, and long-term safety studies to establish Varnya Karma as a fully evidence-based therapeutic modality. The integration of Ayurvedic wisdom with modern scientific methodology holds promise for developing safe and effective treatments for hyperpigmentation disorders.

REFERENCE

- Sharma PV, Dravyaguna Vijnana: Pharmacology of Ayurvedic Drugs. Chaukhamba Orientalia; 2015.
- Mukherjee PK, Maity N, Nema NK, Sarkar BK. Bioactive compounds from natural resources against skin aging. *Phytomedicine*. 2011;19(1):64-73.
- Charaka Samhita. Sutra Sthana, Chapter 4. Varnya Mahakashaya. Chaukhamba Sanskrit Series; 2011.
- JETIR. Varnya Mahakashaya of Charaka Samhita. *JETIR*. 2026;26(2):1-10.
- Mishra B. Bhavaprakasha of Bhavamishra. Chaukhamba Orientalia; 2010.
- Dash B, Kashyap L. *Materia Medica of Ayurveda*. Concept Publishing Company; 2011.
- Lad V. *Textbook of Ayurveda: Fundamental Principles*. Ayurvedic Press; 2002.
- Sharma H, Chandola HM. Ayurvedic concept of skin diseases with special reference to Kushta (leprosy and other

- dermatological disorders). *Anc Sci Life*. 2010;29(4):1-8.
9. Paranjpe P. *Ayurvedic Medicines: The Popular Leads, Emerging Drugs, and Advanced Techniques*. Bharatiya Vidya Bhavan; 2013.
 10. Slominski A, Tobin DJ, Shibahara S, Wortsman J. Melanin pigmentation in mammalian skin and its hormonal regulation. *Physiol Rev*. 2004;84(4): 1155-1228.
 11. Ito S, Wakamatsu K. Quantitative analysis of eumelanin and pheomelanin in humans, mice, and other animals: a comparative review. *Pigment Cell Res*. 2003;16(5):523-531.
 12. Chang TS. An updated review of tyrosinase inhibitors. *Int J Mol Sci*. 2009;10(6): 2440-2475.
 13. Rzepka Z, Buszman E, Beberok A, Wrześniok D. From tyrosine to melanin: significant steps of melanogenesis. *Ann Agric Environ Med*. 2016;23(4): 518-524.
 14. Yonemoto K, Kakehashi A, Sato M, et al. Melanocyte-microenvironment interactions in the skin. *Pigment Cell Melanoma Res*. 2015;28(6):674-683.
 15. Van Niel G, D'Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles. *Nat Rev Mol Cell Biol*. 2018;19(4):213-228.
 16. Hearing VJ. Biogenesis of pigment granules: specialized organelles for specialized jobs. *Pigment Cell Res*. 2005;18(5):344-354.
 17. Decker H, Schweikardt T, Tuzek F. The first crystal structure of tyrosinase: all questions answered? *Angew Chem Int Ed*. 2006;45(26):4546-4550.
 18. Pillaiyar T, Manickam M, Namasivayam V. Skin whitening agents: medicinal chemistry perspective of tyrosinase inhibitors. *J Enzyme Inhib Med Chem*. 2017;32(1):403-425.
 19. Zhang J, Chen H, Li Y, et al. The mechanism of melanogenesis inhibition by glabridin: molecular docking, PKA, and CREB. *J Cosmet Dermatol*. 2019;18(5): 1407-1416.
 20. Alexis AF, Blackcloud P. Clinical evaluation of skin lightening products. *J Drugs Dermatol*. 2013;12(2):147-150.
 21. Sonthalia S, Daulatabad D, Sarkar R. Melasma: a comprehensive overview of treatment options. *J Drugs Dermatol*. 2016;15(6):689-697.
 22. Masamoto Y, Kaido T, Fujishita S, et al. Effect of coenzyme Q10 on DOPA and tyrosine oxidation by mushroom tyrosinase. *Chem Pharm Bull*. 1980;28(9): 2765-2768.
 23. Nair N, Tracas A, Navare J, et al. The pea as a source of bioactive compounds for skin care. *Int J Cosmet Sci*. 2013;35(3):291-297.
 24. Ancans J, Flanagan N, Hoogduijn MJ, et al. UVB-induced melanocyte proliferation occurs in situ in human skin. *J Invest Dermatol*. 2001;117(2): 298-301.
 25. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. *J Immunol Methods*. 1983;65(1-2):55-63.
 26. Prior RL, Wu X, Schaich K. Standardized methods for the determination of antioxidant capacity and phenolics in foods and dietary supplements. *J Agric Food Chem*. 2005;53(10):4290-4302.
 27. Lajis AFB, Hamid M, Ariff SM. A zebrafish embryo as an animal model for the treatment of hyperpigmentation. *Med J Malaysia*. 2018;73(3):31-35.
 28. Tobiishi M, Toyokuni S, Nishiyama S, et al. Pigmentation in intrinsically aged skin of A1 guinea pigs. *Pigment Cell Res*. 2004;17(2):157-163.
 29. Abdel-Malek ZA, Knittel J, Kadearo AL, et al. The melanocortin-1 receptor is a key regulator of melanogenesis. *Ann N Y Acad Sci*. 2008;1126:275-283.
 30. Kimbrough-Green CK, Griffiths CE, Finkel LJ, et al. Topical retinoic acid (tretinoin) for melasma in black patients: a vehicle-controlled clinical trial. *Arch Dermatol*. 1994;130(6):727-733.
 31. Hachiya A, Kobayashi T, Ozawa A, et al. Cross-regulation between AhR and ARNT determines the sensitivity of UVB-mediated skin tanning. *J Invest Dermatol*. 2017;137(6):1376-1385.
 32. Yamamoto Y, Takashima Y, Matsumura M, et al. Evaluation of the melanin distribution in the epidermis using the mexameter. *Skin Res Technol*. 2013;19(4):e375-e381.
 33. Fullerton T, Fischer T, Lahti A, et al. A protocol for assessment of skin colour and erythema. *Skin Res Technol*. 1996;2(1):1-6.
 34. Bakos RM, Blanco M, Bergmann L, et al. Dermoscopy and reflectance confocal microscopy evaluation of equivocal melanocytic lesions. *An Bras Dermatol*. 2011;86(4):671-678.
 35. Chen J, Gao X, Lu Y, et al. VISIA-CR imaging system for facial skin analysis: A validation study. *Skin Res Technol*. 2020;26(4):556-563.
 36. Misra N, Sharma M, Raj K, et al. TLC-bioautographic evaluation of in vitro anti-tyrosinase and anti-cholinesterase potential of Santalum album oil. *Nat Prod Commun*. 2013;8(2):253-256.
 37. Golmohammadzadeh H, Arouiee H, Jaafar H, et al. Does saffron have antisolar and moisturizing effects? *Iran J Pharm Sci*. 2010;6(4):267-270.
 38. *Phyllanthus emblica* branch: A safe and effective ingredient against skin aging. *BMC Complement Med Ther*. 2021;21:222.
 39. Yokota T, Nishio H, Sunscreen H, et al. The inhibitory effect of glabridin from licorice extracts on melanogenesis and inflammation. *Pigment Cell Res*. 1998;11(6):355-361.
 40. Tyrosinase inhibitory potential of purpurin in *Rubia cordifolia*. *Ind Crops Prod*. 2016;83:195-201.
 41. In vitro study on anti-oxidant and anti-inflammatory properties of *Hemidesmus indicus* extracts. *J Ayurveda Integr Med*. 2019;10(2):109-116.
 42. Evaluation of the in vitro anti-tyrosinase activity of *Vetiveria zizanioides*. *J Cosmet Dermatol*. 2020;19(5):1120-1128.
 43. Simmler C, Pauli GF, Chen SN, et al. Phytochemistry and chemotaxonomy of *Glycyrrhiza glabra*. *Fitoterapia*. 2015;103:116-134.
 44. Nerya O, Vaya J, Musa R, et al. Glabridin as a tyrosinase inhibitor: isolation, identification and molecular modeling. *J Nat Prod*. 2003;66(5):678-680.
 45. Lee SY, Baek N, Nam TY. Natural inhibitors for melanogenesis. *Ann Dermatol*. 2016;28(2):129-136.
 46. Choi SY, Kim S, Lee Y, et al. The whitening effect of *Artemisia capillaris* extracts on B16 melanoma cells and zebrafish. *Nat Prod Res*. 2018;32(8): 931-936.
 47. Lee YM, Kim Y, Lee M, et al. The anti-melanogenic effect of *Gastrodia elata* Blume extract on B16F10 melanoma cells and

- zebrafish. *Molecules*. 2019;24(17):3083.
48. Huh CH, Seo KI, Park JY, et al. A randomized, double-blind, placebo-controlled, split-face study on the efficacy of kinetin in the treatment of mild to moderate photodamage. *J Cosmet Dermatol*. 2007;6(4):233-236.
49. Wang T, Wang C, Zhang X, et al. Efficacy and safety of topical therapy with botanical products for melasma: A systematic review and meta-analysis. *Front Med*. 2022;8:797890.
50. Parvizi MM, Jafarian AH, Yousefi M, et al. Clinical trials conducted on herbal remedies for the treatment of melasma: A scoping review. *J Cosmet Dermatol*. 2024;23(4):1123-1135.
51. Kim J, Lee J, Kim Y, et al. Inhibition effect of Ginkgo biloba extract on ultraviolet B-induced matrix metalloproteinase-1 expression in normal human fibroblasts. *J Dermatol*. 2005;32(4):234-242.
52. Sato K, Takahashi H, Toriyama M, et al. Down-regulation of tyrosinase expression by acetylsalicylic acid in murine B16 melanoma. *J Pharmacol Sci*. 2008;106(1):164-168.
53. Patwardhan B, Mashelkar RA. Traditional medicine-inspired approaches to drug discovery: can Ayurveda show the way forward? *Drug Discov Today*. 2009;14(17-18):804-811.
54. Briganti S, Camera E, Picardo M. Chemical and instrumental approaches to treat hyperpigmentation. *Pigment Cell Res*. 2003;16(2):101-110.
55. *Phyllanthus emblica* L. (amla) branch: A safe and effective ingredient against skin aging. *J Ethnopharmacol*. 2021;272:113931.
56. Thring TSA, Hili P, Naughton DP. Anti-collagenase, anti-elastase and anti-oxidant activities of extracts from 21 plants. *BMC Complement Altern Med*. 2009;9:27.
57. Slominski A, Wortsman J, Plonka PM, et al. Hair follicle pigmentation. *J Invest Dermatol*. 2005;124(1):13-21.
58. Kimbrough-Green CK, Griffiths CE, Finkel LJ, et al. Topical retinoic acid (tretinoin) for melasma in black patients: a vehicle-controlled clinical trial. *Arch Dermatol*. 1994;130(6):727-733.
59. Grimes PE. Melasma: Etiologic and therapeutic considerations. *Arch Dermatol*. 1995;131(12):1453-1457.
60. Wagner H, Ulrich-Merzenich G. Synergy research: approaching a new generation of phytopharmaceuticals. *Phytomedicine*. 2009;16(2-3):97-110.
61. Fabricant DS, Farnsworth NR. The value of plants used in traditional medicine for drug discovery. *Environ Health Perspect*. 2001;109(Suppl 1):69-75.
62. Patwardhan B, Warude D, Pushpangadan P, Bhatt N. Ayurveda and traditional Chinese medicine: a comparative overview. *Evid Based Complement Alternat Med*. 2005;2(4):465-473.
63. Vaidya ADB. Reverse pharmacology correlates: Ayurvedic drug discovery and development. *J Ayurveda Integr Med*. 2010;1(1):5-15.